To compare the 24-hour efficacy and safety, measured every three hours, of the dorzolamide/timolol fixed combination given twice daily versus latanoprost and placebo each given once daily.

Study Type: Interventional

Study Design: Treatment, Randomized, Double-Blind, Active Control, Crossover Assignment

Intervention(s) in this Clinical Trial

• Drug: timolol maleate 0.5%
• Drug: dorzolamide/timolol maleate fixed combination
• Drug: latanoprost 0.005%
• Drug: placebo

Inclusion Criteria:

• adults with primary open-angle, pigmentary, or exfoliation glaucoma, or ocular hypertenstion
• intraocular pressure should be 22 to 30 mm Hg inclusive on timolol BID at the 08:00 H
• ETDRS visual acuity must be 1.0 or better in both eyes

Exclusion Criteria:

• any contraindications to study medications
• any anticipated change in systemic hypertensive therapy during the trial

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Sponsor: Pharmaceutical Research Network

Overall Clinical Trial Officials and Contacts

William C. Stewart, MD Study Director Pharmaceutical Research Network, LLC  

Information obtained from ClinicalTrials.gov on October 10, 2008

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00273429

Study ID Number: PRN 04-015

ClinicalTrials.gov Identifier: NCT00273429

Health Authority: United States: Institutional Review Board